BRTX - BioRestorative Therapies, Inc. Stock Price, Fair Value and News

1.33USD-0.05 (-3.62%)Delayed as of 17 May 2024, 10:59 am ET

Market Summary

USD1.33-0.05

Delayedas of 17 May 2024, 10:59 am

-3.62%

BRTX Stock Price

View Fullscreen

BRTX RSI Chart

BRTX Valuation

Market Cap

9.3M

Price/Earnings (Trailing)

-0.65

Price/Sales (Trailing)

33.34

Price/Free Cashflow

-1.42

BRTX Price/Sales (Trailing)

BRTX Profitability

Return on Equity

-124.83%

Return on Assets

-114.3%

Free Cashflow Yield

-70.34%

BRTX Fundamentals

BRTX Revenue

Revenue (TTM)

280.2K

Rev. Growth (Yr)

-39.44%

Rev. Growth (Qtr)

-25.04%

BRTX Earnings

Earnings (TTM)

-14.4M

Earnings Growth (Yr)

35.02%

Earnings Growth (Qtr)

3.43%

Breaking Down BRTX Revenue

52 Week Range

1.327.13

(Low)(High)

Last 7 days

-3.5%

Last 30 days

5.3%

Last 90 days

-7.4%

Trailing 12 Months

-72.7%

How does BRTX drawdown profile look like?

BRTX Financial Health

Current Ratio

10.71

BRTX Investor Care

Shares Dilution (1Y)

79.69%

Diluted EPS (TTM)

-3.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	135.1K	0	217.8K	280.2K
2022	82.6K	81.6K	81.6K	119.8K
2021	111.6K	79.7K	46.1K	75.0K
2020	1.5M	1.0M	581.1K	137.3K
2019	2.0M	2.2M	2.1M	1.9M
2018	528.5K	975.9K	1.4M	1.9M
2017	1.8M	2.1M	2.2M	81.0K
2016	1.3M	1.7M	1.9M	1.6M
2015	1.4M	989.4K	1.1M	1.4M
2014	816.5K	1.2M	1.2M	1.3M
2013	1.6M	1.3M	1.1M	779.5K
2012	947.6K	1.2M	1.5M	1.7M
2011	0	0	0	682.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioRestorative Therapies, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	silva francisco	bought	8,250	1.25	6,600	vp of research and development
Apr 08, 2024	silva francisco	bought	1,979	1.15885	1,708	vp of research and development
Mar 18, 2024	alstodt lance	sold (taxes)	-24,509	1.39	-17,633	president, ceo, cob
Mar 18, 2024	silva francisco	sold (taxes)	-23,898	1.39	-17,193	vp of research and development
Feb 09, 2024	broadrick dale	bought	113,574	1.32	86,041	-
Feb 08, 2024	broadrick dale	bought	112,059	1.34	83,626	-
Feb 08, 2024	broadrick dale	bought	92,448	1.25	73,959	-
Feb 07, 2024	broadrick dale	bought	50,196	1.38	36,374	-
Dec 01, 2023	broadrick dale	sold	-469	1.877	-250	-
Nov 27, 2023	broadrick dale	sold	-525	1.89	-278	-

Which funds bought or sold BRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-6,752	28,233	-%
May 15, 2024	MORGAN STANLEY	new	-	13,800	13,800	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-94.00	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	232,591,000	232,591,000	0.13%
May 15, 2024	Tower Research Capital LLC (TRC)	added	215	2,203	3,672	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-34,276	-	-%
May 15, 2024	Mariner, LLC	sold off	-100	-46,683	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	25,070	25,070	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	reduced	-6.52	-18,175	55,830	-%
May 13, 2024	UBS Group AG	added	793	995	1,159	-%

Are Funds Buying or Selling BRTX?

Are funds buying BRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BRTX

No. of Funds

Unveiling BioRestorative Therapies, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	broadrick dale	14.1%	926,376	SC 13D/A
Feb 15, 2024	silva francisco	10.7%	764,557	SC 13D/A
Feb 15, 2024	alstodt lance	11.2%	799,136	SC 13D/A
Feb 14, 2024	auctus fund management llc	9.9%	482,315	SC 13G/A
Feb 17, 2023	silva francisco	12.5%	505,125	SC 13D/A
Feb 17, 2023	alstodt lance	12.7%	513,784	SC 13D/A
Feb 14, 2023	auctus fund management llc	9.9%	376,004	SC 13G/A
Feb 07, 2023	hudson bay capital management lp	0%	0	SC 13G/A
Jul 14, 2022	auctus fund management llc	5.8%	210,000	SC 13G
Jun 21, 2022	broadrick dale	16.8%	611,745	SC 13D/A

Recent SEC filings of BioRestorative Therapies, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	NT 10-Q	NT 10-Q
Apr 19, 2024	424B3	Prospectus Filed
Apr 18, 2024	EFFECT	EFFECT
Apr 17, 2024	CORRESP	CORRESP
Apr 12, 2024	S-1/A	Initial Public Offering
Apr 11, 2024	UPLOAD	UPLOAD
Apr 10, 2024	4	Insider Trading
Apr 03, 2024	S-1	Initial Public Offering
Apr 01, 2024	10-K	Annual Report
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to BioRestorative Therapies, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

BioRestorative Therapies, Inc. News

Latest updates

BioRestorative Therapies, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-25.0%	62,467	83,333	31,300	103,146	-	654	16,000	64,955	-	1,648	8,389	36,055	33,594	33,589	219,345	405,101	373,975	533,873	599,734	602,344	417,601
Operating Expenses	3.3%	3,239,982	3,135,143	5,810,398	4,685,604	4,638,700	4,699,728	5,069,793	4,014,267	3,696,687	3,570,263	15,072,656	874,850	625,265	480,588	844,989	2,187,869	1,856,996	2,159,804	2,357,336	2,206,909	1,214,670
S&GA Expenses	13.2%	2,559,351	2,260,319	4,299,153	4,011,983	3,649,530	3,624,504	4,294,456	3,858,200	3,459,277	3,401,497	14,896,413	660,883	340,485	179,323	602,641	1,326,559	917,027	1,075,359	1,286,759	1,090,307	284,472
R&D Expenses	-22.2%	680,631	874,824	1,511,245	673,621	989,170	1,075,224	775,337	165,496	237,410	160,898	165,254	177,912	251,036	261,553	186,328	415,794	409,815	441,723	455,006	375,769	357,436
EBITDA Margin	-	-	-	-	-	-	-	-	-	-202	-117	-83.70	-67.93	-15.78	-8.82	-6.13	-4.64	-4.25	-4.20	-4.44	-4.90	-5.27
Interest Expenses	510.1%	376,223	61,667	18,216	116,115	-28,841	-46,613	-29,011	-3,416,917	495,545	-	-	-	-	-	-	122,633	98,157	8,367	126,169	23,162	12,270
EBT Margin	-	-	-	-	-	-	-	-	-	-204	-118	-84.61	-68.81	-16.25	-9.21	-6.43	-4.94	-4.48	-4.39	-4.64	-5.05	-5.43
Net Income	3.4%	-2,825,218	-2,925,492	-5,684,222	-4,347,553	-4,655,825	-4,675,241	-4,816,150	-20,403,138	-4,184,232	-4,062,595	-15,653,330	-5,761,312	-836,263	2,875,660	-7,550,772	-1,550,555	-5,056,973	-4,157,190	-3,883,172	-3,570,459	-2,925,261
Net Income Margin	32.7%	-51.44	-76.44	-125	-132	-556	-828	-794	-1,283	-657	-471	-291	-146	-13.18	-	-	-	-	-	-	-	-
Free Cashflow	-49.6%	-1,813,239	-1,211,948	-2,360,022	-1,615,930	-1,427,051	-1,388,796	-1,704,207	-1,145,014	-629,364	-741,829	-813,701	-572,120	-523,061	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.6%	12,612	13,801	13,300	14,081	16,435	17,920	19,441	20,919	22,453	2,175	2,885	3,701	4,347	1,429	1,613	1,378	1,466	1,458	2,432	1,584	1,192
Current Assets	-9.6%	11,391	12,604	12,044	12,783	15,128	16,888	18,324	19,879	21,468	1,170	1,829	2,594	3,187	214	344	53.00	69.00	201	1,357	647	181
Cash Equivalents	-63.7%	884	2,437	1,784	1,836	1,714	6,573	17,934	19,323	21,027	1,130	1,759	2,501	3,065	176	298	5.00	2.00	98.00	1,284	496	118
Net PPE	16.2%	356	306	314	304	261	231	267	140	38.00	10.00	13.00	16.00	22.00	29.00	35.00	43.00	68.00	106	136	141	175
Liabilities	9.1%	1,063	975	896	594	603	916	856	762	856	7,054	6,694	6,396	5,679	16,522	16,054	18,914	14,242	13,887	11,375	9,237	9,833
Current Liabilities	14.0%	1,063	933	813	470	440	717	622	494	364	873	1,326	1,292	1,045	1,374	882	18,416	13,721	13,715	11,143	8,728	9,255
Shareholder's Equity	-10.0%	11,548	12,826	12,404	13,487	15,832	17,004	18,586	20,157	21,597	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.7%	-167,056	-164,231	-161,305	-158,325	-152,640	-148,293	-143,637	-138,962	-134,146	-113,742	-109,558	-105,496	-89,842	-84,081	-83,245	-86,120	-78,570	-77,019	-71,962	-67,805	-63,922
Additional Paid-In Capital	0.9%	178,590	177,043	173,695	171,797	168,457	165,282	162,207	159,103	155,727	108,864	105,750	102,484	88,511	68,829	68,645	68,425	65,794	64,567	63,000	60,138	55,280
Shares Outstanding	0.8%	4,707	4,668	3,983	3,768	3,678	3,603	3,581	3,523	3,520	872	837	794	716	346	-	-	-	-	-	-	-
Float	-	-	-	13,664	-	-	-	8,495	-	-	-	19,924	-	-	-	159	-	-	-	5,040	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-50.7%	-1,743	-1,156	-1,151	-2,348	-1,615	-1,451	-1,251	-1,594	-1,145	-629	-741	-813	-572	-523	-420	-448	-1,810	-1,710	-1,416	-1,980	-1,553
Share Based Compensation	-2.0%	1,464	1,494	1,486	3,339	3,058	3,075	3,104	3,376	3,179	2,927	2,926	14,077	66.00	185	219	222	519	-	-	786	1,147
Cashflow From Investing	536.6%	101	-23.06	666	2,509	-3,243	-9,908	-137	-109	-	-	-	-	-	-	-	-	-	-6.26	-	-	-
Cashflow From Financing	-95.4%	86.00	1,854	-	-	-	-	-	-	21,073	-	-	250	3,461	401	714	452	1,715	531	2,234	2,359	1,565

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BRTX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues, net	$ 145,800	$ 119,800
Operating Expenses:
Research and development	4,034,591	3,513,352
General and administrative	11,331,983	15,580,473
Total Operating Expenses	15,366,574	19,093,825
Loss From Operations	(15,220,774)	(18,974,025)
Other Income:
Interest income	(552,293)	(11,650)
Gain on PPP loan forgiveness		(250,000)
Grant income	(83,333)	(110,518)
Other income	(169,664)	(107,088)
Total Other Income	(805,290)	(479,256)
Net Loss	$ (14,415,484)	$ (18,494,769)
Net Loss Per Share - Basic	$ (3.42)	$ (5.11)
Net Loss Per Share - Diluted	$ (3.42)	$ (5.11)
Weighted Average Common Shares Outstanding - Basic	4,218,347	3,617,858
Weighted Average Common Shares Outstanding - Diluted	4,218,347	3,617,858

BRTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 884,377	$ 1,713,772
Investments held in marketable securities	10,181,618	13,035,636
Accounts receivable	19,300	16,000
Prepaid expenses and other current assets	305,231	363,082
Total Current Assets	11,390,526	15,128,490
Property and equipment, net	356,055	261,003
Right-of-use assets	151,447	241,760
Intangible assets, net	713,692	803,438
Total Assets	12,611,720	16,434,691
Current Liabilities:
Accounts payable	189,389	170,902
Accrued expenses and other current liabilities	711,686	130,072
Lease liability, current portion	162,317	139,328
Total Current Liabilities	1,063,392	440,302
Lease liability, net of current portion		162,317
Total Liabilities	1,063,392	602,619
Commitments and contingencies
Stockholders’ Equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized; 4,706,917 and 3,677,775 shares issued and outstanding at December 31, 2023 and 2022, respectively	471	369
Additional paid-in capital	178,590,256	168,457,418
Accumulated deficit	(167,056,381)	(152,640,897)
Total Stockholders’ Equity	11,548,328	15,832,072
Total Liabilities and Stockholders’ Equity	12,611,720	16,434,691
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value	$ 13,982	$ 15,182

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

CEO	Mr. Lance Alstodt
WEBSITE	biorestorative.com
INDUSTRY	Biotechnology
EMPLOYEES	10

BioRestorative Therapies, Inc. Frequently Asked Questions

What is the ticker symbol for BioRestorative Therapies, Inc.? What does BRTX stand for in stocks?

BRTX is the stock ticker symbol of BioRestorative Therapies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioRestorative Therapies, Inc. (BRTX)?

As of Thu May 16 2024, market cap of BioRestorative Therapies, Inc. is 9.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BRTX stock?

You can check BRTX's fair value in chart for subscribers.

What is the fair value of BRTX stock?

You can check BRTX's fair value in chart for subscribers. The fair value of BioRestorative Therapies, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioRestorative Therapies, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioRestorative Therapies, Inc. a good stock to buy?

The fair value guage provides a quick view whether BRTX is over valued or under valued. Whether BioRestorative Therapies, Inc. is cheap or expensive depends on the assumptions which impact BioRestorative Therapies, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BRTX.

What is BioRestorative Therapies, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, BRTX's PE ratio (Price to Earnings) is -0.65 and Price to Sales (PS) ratio is 33.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioRestorative Therapies, Inc.'s stock?

In the past 10 years, BioRestorative Therapies, Inc. has provided 0.058 (multiply by 100 for percentage) rate of return.